Commentary and thoughts on health care
Drug companies indicate that price increases are coming in 2019 adding more fuel to the fire for “Medicare for all”. The average American is heavier than at the start of the 21st Century — and very close to being obese, according to the Centers for Disease Control data on body metrics. Nearly three in 10 Americans are delaying healthcare treatments because of their cost, a Gallup survey said Monday. M ore than one-third of women in the U.S. report skipping needed medical care because of costs, a far higher rate than the other countries included in the study. After climbing modestly between 2011 and 2016, average premiums for employer health plans rose sharply in 2017. Continue reading
The American healthcare system is a hellish tangle of bureaucracy, with various inefficiencies and injustices.
A sensible healthcare system would have done something about for-profit drug companies who continually raise prices.
America already pays enough to fund two generous universal healthcare systems for its citizenry.
The overall diabetes rate in the U.S. adult population is growing, up from 10.8% in 2008-2009 to 11.5% in 2016-2017. The rate increase has resulted in about 1.7 million more Americans with diabetes diagnoses now than would have been the case had the rate not changed since 2008-2009.
Even more alarming is that obesity, a key risk factor in the development of type 2 diabetes, has climbed by 2.3 points since 2008-2009, to reach 28.3% nationally in 2016-2017.
Americans spend a lot more money on hospital and physician care than prescription drugs, but pharmaceutical companies pocket a lot more of than other parts of the industry. (Source:
Axios) 63% of the profit total went to drug companies, even though they collected 23% of the revenue
Pfizer had the highest profit total ($4.1 billion) of any publicly traded health care company in the third quarter.
Of the 19 companies that tallied at least $1 billion of third-quarter profit, 14 were drug companies.
Republicans have indicated that they are willing to work with democrats on drug pricing initiatives.
Drug companies are focusing lobbying efforts to use a possible lame-duck session of Congress to peel back a legislative loss they suffered earlier this year.
Pharma is making a lobbying push to roll back seniors’ drug discounts at a time when they are reporting near record profits.
So far in 2018, PhRMA spent more than $20 million, according to the Center for Responsive Politics, and was the third-largest spender.
62 percent of cancer patients report being in debt due to their treatment.
55 percent accrue at least $10,000 in debt, while 3 percent file for bankruptcy. Almost 700,000 people in the U.S. declare bankruptcy due medical bills.
American’s are sick and tired of a healthcare system that costs too much and provides too little.
[inlinetweet prefix=”” tweeter=”” suffix=””]After reporting a 45% increase in quarterly profit Pfizer said “it’s business as normal”.[/inlinetweet]
Drug companies have made clear that they’ll never voluntarily reduce prices.
The pharma industry has spent more than $216 million on lobbying this year.
“Telling companies to voluntarily lower their prices and expecting it to happen on a consistent basis is not a realistic long-term policy proposition,” said Anthony T. LoSasso, a professor of health policy and administration at the University of Illinois at Chicago.